GKTRF yields 1.82% · PFE yields 6.13%● Live data
📍 GKTRF pulled ahead of the other in Year 1
Combined, GKTRF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GKTRF + PFE for your $10,000?
GEK TERNA Holdings, Real Estate, Construction S.A., together with its subsidiaries, engages in the construction, real estate, mining, electricity, and concession businesses in Greece, the Balkans, the Middle East, Eastern Europe, the United States, and internationally. The company is involved in the construction of motorways, rail networks, buildings, hospitals, museums, industrial facilities, hydroelectric projects, dams, power plants, etc. for public and private sectors; and the financing, management, and commercial operation of concession projects, such as motorways and parking stations. It also develops and operates wind farms, hydroelectric projects, waste treatment and biogas production plants, and photovoltaic parks, as well as develops pumped storage and infrastructure projects. In addition, the company produces 895.3 MW of electric energy and trades in natural gas. Further, it engages in the acquisition, development, and exploitation of real estate properties, including business centers, industrial parks, entertainment parks, residential properties, hotels, etc.; production of quarry products; and exploitation of magnesite quarries. Additionally, the company operates thermal power plants with a total installed capacity of 147 MW and 435 MW in Viotia, Greece. GEK TERNA Holdings, Real Estate, Construction S.A. was formerly known as Ermis Real Estate Constructions Enterprises S.A. The company was founded in 1960 and is headquartered in Athens, Greece.
Full GKTRF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.